{"name":"Schrödinger Inc.","slug":"schrodinger","ticker":"SDGR","exchange":"NASDAQ","domain":"schrodinger.com","description":"Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.","hq":"New York, NY","founded":2016,"employees":"850","ceo":"Ramy Farid","sector":"Computational Drug Discovery","stockPrice":12.76,"stockChange":0.01,"stockChangePercent":0.08,"marketCap":"$953M","metrics":{"revenue":254904992,"revenueGrowth":-1.6,"grossMargin":55.3,"rdSpend":0,"netIncome":-103483000,"cash":398959008,"dividendYield":0,"peRatio":-8.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Ligandrol (LGD-4033) patent cliff ($100M at risk)","drug":"Ligandrol (LGD-4033)","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Ricolinostat patent cliff ($50M at risk)","drug":"Ricolinostat","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Schrödinger Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Schrödinger reported revenue of $123.4 million for the fourth quarter and $444.8 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Schrödinger Enters into Collaboration with Pfizer to Develop Novel Therapeutics","summary":"Schrödinger entered into a collaboration with Pfizer to develop novel therapeutics using its computational drug discovery platform.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"FDA Grants Orphan Drug Designation to Schrödinger's Ricolinostat for the Treatment of Multiple Myeloma","summary":"The FDA granted orphan drug designation to Ricolinostat for the treatment of multiple myeloma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNZmtFbjZKZlZtRTlieTBOTTROYmFFRmVlckNGZHc0NXdzTEJSQ25RMWl6b0xUTXhrdmQ4LWEzREpYc2FwdThpamtGVTM0UlNrbXRWRVVLLVNvQUhCdm84UktKaGJoZ0RtNVo1bTJxU0NBUnNRT2FXaWlkanF2a0V3LUxaX253OGFubGVJaS1xN1pYM3YzQzdhV1BPaUFJTnpITElQV2dHdy1kSnVDb1I5VDZKZw?oc=5","date":"2026-04-01","type":"pipeline","source":"Seeking Alpha","summary":"SchröDinger: Transition Pressure And Competition Offset Ecosystem Strength (NASDAQ:SDGR) - Seeking Alpha","headline":"SchröDinger: Transition Pressure And Competition Offset Ecosystem Strength (NASDAQ:SDGR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE00SHJsd0FsNUJzSDI5U2lfeG16b0pvTEo4T0hFRm1PbktJclZsS0laUG1ib3hEZkU1LTJ6bzhvOXZXaVdYeVNOcF9fZnVQOW1ubFF5QnlULXN4dEJtV3VuLUVQVjdEVzdEM3JTb0c1NUVyaDdiQm1Hbw?oc=5","date":"2026-03-05","type":"pipeline","source":"Nanalyze","summary":"Schrödinger Stock – A Dead Cat Bounce? - Nanalyze","headline":"Schrödinger Stock – A Dead Cat Bounce?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-28","type":"earnings","source":"simplywall.st","summary":"Does Schrödinger’s 2025 Revenue Surge And Narrower Loss Reshape The Bull Case For SDGR? - simplywall.st","headline":"Does Schrödinger’s 2025 Revenue Surge And Narrower Loss Reshape The Bull Case For SDGR?","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQVmlqNGlxbmVpVkVzdmdvVEVfN0JuMEhFdzdLRTB0Y2tlUmxQcTRMMzljNFZPRGFRTDB5azBBUV9MY3Q1VV94bk9PeGxXZDFrSF8yUGtsdFczVVEwbGR1R0lCVDNBV0hLeVRuaDRpelFWYk5oeUtWY2JiSlJuUjBsUDdWQjNQd3FrQmRqWW5xWGtaTVZIS0pkVmg1X3E0SlotRURPazdNcEZFNmMydjBMTmJneHR1alFaMVBUd3Uxb2VZaXRveEZpai1DYTBYZnk3QWhycTFqZw?oc=5","date":"2026-01-09","type":"pipeline","source":"Reuters","summary":"Schrodinger to offer Eli Lilly's AI drug discovery platform on its software - Reuters","headline":"Schrodinger to offer Eli Lilly's AI drug discovery platform on its software","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5GV2tSdkx6b2hma1FNalhjNC1CZ2c3SzhjLVV6VkhIRjRNS2RKTFFQamFhOXdJTmtVQnlCY0F1clVuQmoxV055Y01XWDNSREJqUExYVUlCWkhrcjZZdDRJ?oc=5","date":"2025-11-27","type":"pipeline","source":"Intellectia AI","summary":"5 Best AI Biotech Stocks to Watch in 2026: The Future of Medicine - Intellectia AI","headline":"5 Best AI Biotech Stocks to Watch in 2026: The Future of Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5UcUJuVWdLN2NFdTk2b0J0Uk5td1FRcGhyaW9lZFhrWmM5czBRZlFkZzcxQjFVaGZjLUd4cWppbkN2UVQ3OXV0a1pnREpkcGhIcE15X0FCSzBtQ2h3clhrRWtSYmlQbmk3X3Z2YkFrM3Y0bHpXVl9GVWw1U3UwUQ?oc=5","date":"2025-08-21","type":"pipeline","source":"Seeking Alpha","summary":"Schrödinger: A Complex Story With Many Moving Parts (NASDAQ:SDGR) - Seeking Alpha","headline":"Schrödinger: A Complex Story With Many Moving Parts (NASDAQ:SDGR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQbXV2VWRnYjhTZmljTHZLNlhGMENPQUFnVHRXOEphRzltV2k2UE1yekhNc05JbFd2U3B5c19FTjJuRU42VnkzUWFHODdHRjdhSW5ycmtlTjFSeHE0REIwS1NqNV9uZW41YzlIdzZlbC1FRlU3V2l0YlV5QmZNMW41N2FvOFNXVHlmUmhZS2d3YXh4WEwxcmVYanU5Wm5DZ0EzOThrWG9ibGlEVHUyaENmbnZOV3ZPS0hqTUp0UkFzaEFBbE5CQzlROVlJd2pwQjMySXlyRVd3MDJXSDR4b2NLNk9VdVpweTJG?oc=5","date":"2025-07-16","type":"deal","source":"The Globe and Mail","summary":"Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - The Globe and Mail","headline":"Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOSVQzMkNRLW1EQmlPY0c4bjZLelpDNVBOZTZ6dTYtc1ZmX1ZYMDUwS3o2b3MzWUx2M2l3Uk96NXFmSGYyS3pXN1NDajliUnQzU1NxcUtQNENRZHRNQ3djLVZkSlA5U3lrU2ttYXcyX21UZHJYQXZjcXhFYW14dkxjNjhYUjE5enFpQmVaOS1lQUpWWXA5Y3VtUUxSdnNtSENycFE3aGt5U01lYkFVcWZBVE5tdXRDZXFHMU85aUhwWi1hVDc2LXVmSXVFejd6LU84a1pVZkVQTGluZXNZS2MwRFVJLWY4bmtrSkE?oc=5","date":"2025-07-02","type":"pipeline","source":"The Globe and Mail","summary":"Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? - The Globe and Mail","headline":"Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1LUldMTmh4WmRWdzZseVpOZGNETUhmVlE1NUVXZjh0OEFYVTZKN2RkcFlwX203aUVJSV9yZEhtQmNwYmxvX3c3UFVLQXJIWkNLbXhnXzVXbkY2S1NrMWY1V0VEVzdIMFY5R0JidnIySlhic2I1RlAyNg?oc=5","date":"2025-05-27","type":"pipeline","source":"Yahoo Finance","summary":"RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? - Yahoo Finance","headline":"RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiR0FVX3lxTE5TTVBrX1lpTXp1a0hpLW5hWXpmXzEzZjAtZlUxNkJia2NETFlpMGlVUmhDWjRnWVdITmhPTTJoTTZRUW9VQkFz?oc=5","date":"2025-01-22","type":"deal","source":"Hunterbrook","summary":"Schrödinger: The Nvidia Biotech Partner Jensen Huang Told To “Think Bigger” - Hunterbrook","headline":"Schrödinger: The Nvidia Biotech Partner Jensen Huang Told To “Think Bigger”","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPelRlZERnblRWT0xJTVh5OGdHR3hCelJWUE4yX3NFZi0wNkJZR1NjdXAzNDhMWXFmcDRIdUhUeDZUaWlCRDB4NDcwNHZtbDI0azRMelN0YUJuYUd3WkRxVWh1V0VVdm9DMFh6OFNYSmNURjVpZzI2cnE0V0lndDZzWHBZSVVfZElRWnJReWFOVjBuWW9KN2lJR1JBTGlPYUNzcUM2TEJMZUtfbVEzV0Y3MEdvYm1mbEduaXV1cHhBUFV1WEd0SzJNa0R3VHdKaGpPWmJVSA?oc=5","date":"2025-01-13","type":"pipeline","source":"BioSpace","summary":"Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities - BioSpace","headline":"Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBCcDRxM09PMXZ5NWpDWmlIeFNiQ1BpYWdDWFVDZHBsZ0ZWUVdlMVpSRWJ4a2x4X0VaM3pHQ1VqdjVkNlpaSVVpM25RaUtOVlV2?oc=5","date":"2023-11-22","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Ligandrol (LGD-4033)","drugSlug":"lgd-4033","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Ricolinostat","drugSlug":"ricolinostat","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":50000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Merck & Co.","Eli Lilly and Company"],"therapeuticFocus":["Oncology","Musculoskeletal Disorders"],"financials":{"source":"yahoo_finance","revenue":255869000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":255869000},{"period":"2024-12-31","value":207539000},{"period":"2023-12-31","value":216666000},{"period":"2022-12-31","value":180955000}],"grossProfit":142614000,"grossProfitHistory":[{"period":"2025-12-31","value":142614000},{"period":"2024-12-31","value":132083000},{"period":"2023-12-31","value":140692000},{"period":"2022-12-31","value":101022000}],"rdSpend":173138000,"rdSpendHistory":[{"period":"2025-12-31","value":173138000},{"period":"2024-12-31","value":201785000},{"period":"2023-12-31","value":181766000},{"period":"2022-12-31","value":126372000}],"sgaSpend":136372000,"operatingIncome":-166896000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-166896000},{"period":"2024-12-31","value":-209296000},{"period":"2023-12-31","value":-177448000},{"period":"2022-12-31","value":-146817000}],"netIncome":-103265000,"netIncomeHistory":[{"period":"2025-12-31","value":-103265000},{"period":"2024-12-31","value":-187123000},{"period":"2023-12-31","value":40720000},{"period":"2022-12-31","value":-149186000}],"eps":-1.41,"epsHistory":[{"period":"2025-12-31","value":-1.41},{"period":"2024-12-31","value":-2.57},{"period":"2023-12-31","value":0.54},{"period":"2022-12-31","value":-2.1}],"cash":230517000,"cashHistory":[{"period":"2025-12-31","value":230517000},{"period":"2024-12-31","value":147326000},{"period":"2023-12-31","value":155315000},{"period":"2022-12-31","value":90474000}],"totalAssets":726160000,"totalLiabilities":362107000,"totalDebt":109228000,"equity":364053000,"operatingCashflow":13899000,"operatingCashflowHistory":[{"period":"2025-12-31","value":13899000},{"period":"2024-12-31","value":-157368000},{"period":"2023-12-31","value":-136733000},{"period":"2022-12-31","value":-119683000}],"capex":-1442000,"capexHistory":[{"period":"2025-12-31","value":-1442000},{"period":"2024-12-31","value":-7311000},{"period":"2023-12-31","value":-13403000},{"period":"2022-12-31","value":-8014000}],"freeCashflow":12457000,"dividendsPaid":null,"buybacks":null,"employees":850,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":33051000,"ebit":-17157000,"ebitda":-15720000,"period":"2025-12-31","revenue":87235000,"epsBasic":null,"netIncome":32511000,"rdExpense":41399000,"epsDiluted":null,"grossProfit":57293000,"operatingIncome":-17157000},{"sga":31229000,"ebit":-45947000,"ebitda":-44482000,"period":"2025-09-30","revenue":54324000,"epsBasic":-0.45,"netIncome":-32795000,"rdExpense":42757000,"epsDiluted":-0.45,"grossProfit":28039000,"operatingIncome":-45947000},{"sga":35923000,"ebit":-52903000,"ebitda":-51372000,"period":"2025-06-30","revenue":54759000,"epsBasic":-0.59,"netIncome":-43173000,"rdExpense":43138000,"epsDiluted":-0.59,"grossProfit":26158000,"operatingIncome":-52903000},{"sga":36169000,"ebit":-50889000,"ebitda":-49300000,"period":"2025-03-31","revenue":59551000,"epsBasic":-0.82,"netIncome":-59808000,"rdExpense":45844000,"epsDiluted":-0.82,"grossProfit":31124000,"operatingIncome":-50889000},{"sga":35480000,"ebit":-20712000,"ebitda":-18948000,"period":"2024-12-31","revenue":88317000,"epsBasic":null,"netIncome":-40216000,"rdExpense":49362000,"epsDiluted":null,"grossProfit":64130000,"operatingIncome":-20712000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.52,"netIncome":null,"rdExpense":null,"epsDiluted":-0.52,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":12.76,"previousClose":12.75,"fiftyTwoWeekHigh":27.63,"fiftyTwoWeekLow":10.95,"fiftyTwoWeekRange":"10.945 - 27.63","fiftyDayAverage":12.16,"twoHundredDayAverage":16.48,"beta":1.58,"enterpriseValue":660738240,"forwardPE":-8.2,"priceToBook":2.58,"priceToSales":3.74,"enterpriseToRevenue":2.59,"enterpriseToEbitda":-4.16,"pegRatio":0,"ebitda":-158892000,"ebitdaMargin":-62.3,"freeCashflow":-49420624,"operatingCashflow":-144998000,"totalDebt":107008000,"debtToEquity":34.1,"currentRatio":2.74,"returnOnAssets":-15,"returnOnEquity":-30.1,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":21.12,"targetHighPrice":30,"targetLowPrice":13,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.9,"institutionHeldPercent":97,"sharesOutstanding":65556531,"floatShares":59531495,"sharesShort":10381870,"shortRatio":7.35,"shortPercentOfFloat":13.9,"epsTrailing":-1.4,"epsForward":-1.56,"revenuePerShare":3.46,"bookValue":4.94,"officers":[{"age":60,"name":"Dr. Ramy  Farid Ph.D.","title":"CEO, President & Director"},{"age":57,"name":"Dr. Karen  Akinsanya Ph.D.","title":"President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships"},{"age":72,"name":"Dr. Richard A. Friesner Ph.D.","title":"Co-Founder, Scientific Advisory Chairman and Director"},{"age":40,"name":"Mr. Richie  Jain","title":"Executive VP, CFO & Treasurer"},{"age":54,"name":"Ms. Yvonne  Tran Esq.","title":"Corporate Secretary, Chief Legal & People Officer"},{"age":50,"name":"Mr. Mannix  Aklian","title":"Executive VP, Chief Commercial Officer and Global Head of Software Sales & Marketing"},{"age":null,"name":"Prof. William  Goddard III, Ph.D.","title":"Co-Founder & Scientific Advisor"},{"age":41,"name":"Mr. Kenneth Patrick Lorton","title":"Executive VP, CTO & COO of Software"}],"industry":"Health Information Services","irWebsite":"","website":"https://www.schrodinger.com","phone":"212 295 5800"}}